{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T16:15:19Z","timestamp":1769962519495,"version":"3.49.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007111","name":"Bart","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["PDM\/17\/164"],"award-info":[{"award-number":["PDM\/17\/164"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ijpharm.2018.06.050","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T03:41:53Z","timestamp":1529725313000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded \u201821st Century BA\/BE\u2019 project"],"prefix":"10.1016","volume":"548","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4229-9843","authenticated-orcid":false,"given":"Bart","family":"Hens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick D","family":"Sinko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Job","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"Al-Gousous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloufar","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Ziff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-1790","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-0544","authenticated-orcid":false,"given":"Marival","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James G.","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjang","family":"Talattof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Benninghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Marciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Dickens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerby","family":"Shedden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory E.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon L.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2018.06.050_b0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mrm.21982","article-title":"Quantitative analysis of peristaltic and segmental motion in vivo in the rat small intestine using dynamic MRI","volume":"62","author":"Ailiani","year":"2009","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0015","series-title":"Multi-scale Fluid Mechanics of Nutrient Absorption in the Small Intestine Analyzed with 2d and 3d Lattice Boltzmann Models","author":"Banco","year":"2010"},{"key":"10.1016\/j.ijpharm.2018.06.050_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2004.08.003","article-title":"Hydrodynamics-induced variability in the USP apparatus II dissolution test","volume":"292","author":"Baxter","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0025","doi-asserted-by":"crossref","first-page":"E857","DOI":"10.1208\/aapsj070483","article-title":"Shear-induced variability in the United States Pharmacopeia Apparatus 2: modifications to the existing system","volume":"7","author":"Baxter","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation-permeation interplay: supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0035","unstructured":"Brasseur, J.G., Behafarid, F., Wang, Y., Mudie, D., Amidon, G.L., 2017. Hydrodynamic Influences on Drug Dissolution and Absorption In Vitro and In Vivo, quantified with Mathematical Models and Computer Simulation. In: Presented at the 6th Pharmaceutical Sciences World Congress (FIP PSWC 2017), Stockholm, Sweden."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0040","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jps.21576","article-title":"IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution\/permeation system","volume":"98","author":"Buch","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jps.20495","article-title":"Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model","volume":"95","author":"Carino","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0050","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2982.2001.00281.x","article-title":"High-resolution analysis of the duodenal interdigestive phase III in humans","volume":"13","author":"Castedal","year":"2001","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0055","doi-asserted-by":"crossref","DOI":"10.14227\/DT090202P6","article-title":"An industrial implementation of the biopharmaceutics classification system","author":"Cook","year":"2002","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addr.2016.04.018","article-title":"The solubility-permeability interplay and oral drug formulation design: two heads are better than one","volume":"101","author":"Dahan","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0065","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of model compounds and the Mucosal Barrier Marker 51Cr-EDTA","volume":"14","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0070","unstructured":"European Medicines Agency, 2010. Guideline on the investigation of bioequivalence."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0075","unstructured":"Food & Drug Administration, 2015. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13008","article-title":"Established and emerging methods for assessment of small and large intestinal motility","volume":"29","author":"Gr\u00f8nlund","year":"2017","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejps.2014.07.008","article-title":"Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools","volume":"63","author":"Hens","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejps.2015.05.023","article-title":"Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential","volume":"77","author":"Hens","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0095","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1021\/acs.molpharmaceut.7b00426","article-title":"Low buffer capacity and alternating motility along the human gastrointestinal tract: implications for in vivo dissolution and absorption of ionizable drugs","volume":"14","author":"Hens","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jcpt.12535","article-title":"Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population","volume":"42","author":"Hens","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2018.01.039","article-title":"Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): an in vitro-in silico-in vivo approach","author":"Hens","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4291\/wjgp.v6.i4.140","article-title":"Magnetic resonance imaging biomarkers of gastrointestinal motor function and fluid distribution","volume":"6","author":"Khalaf","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0115","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/acs.molpharmaceut.7b00425","article-title":"In vivo dissolution and systemic absorption of immediate release ibuprofen in human gastrointestinal tract under fed and fasted conditions","volume":"14","author":"Koenigsknecht","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0120","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejps.2015.11.012","article-title":"An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: design, implementation, and evaluation","volume":"82","author":"Kourentas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0130","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1002\/jps.24108","article-title":"In vivo predictive dissolution: transport analysis of the CO2, bicarbonate in vivo buffer system","volume":"103","author":"Krieg","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0135","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/jps.24460","article-title":"In vivo predictive dissolution: comparing the effect of bicarbonate and phosphate buffer on the dissolution of weak acids and weak bases","volume":"104","author":"Krieg","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2004.03.033","article-title":"Shear distribution and variability in the USP Apparatus 2 under turbulent conditions","volume":"279","author":"Kukura","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejps.2013.10.012","article-title":"Oral biopharmaceutics tools - time for a new initiative \u2013 an introduction to the IMI project OrBiTo","volume":"57","author":"Lennern\u00e4s","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0150","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/acs.molpharmaceut.6b00824","article-title":"In vivo predictive dissolution (IPD) and biopharmaceutical modeling and simulation: future use of modern approaches and methodologies in a regulatory context","volume":"14","author":"Lennern\u00e4s","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0155","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/clpt.2013.104","article-title":"Confidence in generic drug substitution","volume":"94","author":"Lionberger","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0160","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1021\/acs.molpharmaceut.5b00135","article-title":"In vitro dissolution of fluconazole and dipyridamole in gastrointestinal simulator (GIS), predicting in vivo dissolution and drug-drug interaction caused by acid-reducing agents","volume":"12","author":"Matsui","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0165","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.xphs.2016.02.020","article-title":"The evaluation of in vitro drug dissolution of commercially available oral dosage forms for itraconazole in gastrointestinal simulator with biorelevant media","volume":"105","author":"Matsui","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0170","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/acs.molpharmaceut.6b01063","article-title":"Utilization of gastrointestinal simulator, an in vivo predictive dissolution methodology, coupled with computational approach to forecast oral absorption of dipyridamole","volume":"14","author":"Matsui","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0175","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1148\/radiol.13130151","article-title":"Global small bowel motility: assessment with dynamic MR imaging","volume":"269","author":"Menys","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.ijpharm.2018.06.050_b0180","unstructured":"Mudie, D., Brasseur, J.G., Mansfield, J., Wang, Y., Jayaraman, B., Amidon, G.L., 2015. Influence of Fluid Shear Rate on Dissolution Rate of Poorly Soluble Drug Particles; Implications for In vivo Predictive In vitro Dissolution Methodologies and Mechanistic Computational Modeling. In: Presented at the American Association of Pharmaceutical Scientists, Orlando, FL."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0185","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1021\/mp500210c","article-title":"Quantification of gastrointestinal liquid volumes and distribution following a 240\u202fmL dose of water in the fasted state","volume":"11","author":"Mudie","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0190","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/acs.molpharmaceut.7b00095","article-title":"Magnetic resonance imaging quantification of fasted state colonic liquid pockets in healthy humans","volume":"14","author":"Murray","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0195","unstructured":"Pharmaceuticals and Medical Devices Agency, 2012. Guideline for Bioequivalence Studies of Generic Products."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1208\/s12248-008-9027-6","article-title":"In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms","volume":"10","author":"Polli","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0205","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jps.20064","article-title":"Summary workshop report: biopharmaceutics classification system\u2013implementation challenges and extension opportunities","volume":"93","author":"Polli","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0210","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1208\/s12248-008-9040-9","article-title":"Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond","volume":"10","author":"Polli","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0215","unstructured":"Salehi, N., Hens, B., Job, N., Dean, M., Sinko, P., Amidon, G.E., Ziff, R.M., Amidon, G.L., 2017. Towards a physiologically-relevant in vitro system for oral drug product delivery in the gastrointestinal (GI) tract."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0220","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1021\/acs.molpharmaceut.7b00798","article-title":"In vitro characterization of the biomimetic properties of poly(dimethylsiloxane) to simulate oral drug absorption","volume":"14","author":"Sinko","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.09.001","article-title":"Dynamic dissolution-\/permeation-testing of nano- and microparticle formulations of fenofibrate","volume":"96","author":"Sironi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0230","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1021\/acs.molpharmaceut.5b00602","article-title":"Analysis of intra- and intersubject variability in oral drug absorption in human bioequivalence studies of 113 generic products","volume":"12","author":"Sugihara","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0235","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/acs.molpharmaceut.5b00774","article-title":"Gastrointestinal motility variation and implications for plasma level variation: oral drug products","volume":"13","author":"Talattof","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","article-title":"The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC","volume":"57","author":"Tsume","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib","volume":"76","author":"Tsume","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0250","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2017.02.042","article-title":"The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS)","volume":"102","author":"Tsume","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0255","unstructured":"U.S. Government Printing Office, 2003. Code of Federal Regulations Title 21\u2014Food and Drugs. Part 320\u2014Bioavailability and Bioequivalence Requirements. [WWW Document]. URL https:\/\/www.gpo.gov\/fdsys\/pkg\/CFR-2003-title21-vol1\/content-detail.html (accessed 12.7.17)."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0260","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2015.11.048","article-title":"Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms","volume":"498","author":"Verwei","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0265","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jmri.22529","article-title":"Assessment of small bowel motility function with cine-MRI using balanced steady-state free precession sequence","volume":"33","author":"Wakamiya","year":"2011","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.ijpharm.2018.06.050_b0270","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1098\/rsta.2010.0090","article-title":"A multiscale lattice Boltzmann model of macro- to micro-scale transport, with applications to gut function","volume":"368","author":"Wang","year":"2010","journal-title":"Philos. Trans. R. Soc. London A: Math., Phys. Eng. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0275","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/mp2002818","article-title":"Comparison and analysis of theoretical models for diffusion-controlled dissolution","volume":"9","author":"Wang","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0280","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1002\/jps.24472","article-title":"Analysis of diffusion-controlled dissolution from polydisperse collections of drug particles with an assessed mathematical model","volume":"104","author":"Wang","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2982.1999.00135.x","article-title":"Validation of antroduodenal motility measurements made by echo-planar magnetic resonance imaging","volume":"11","author":"Wright","year":"1999","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0290","article-title":"Measurement of in vivo gastrointestinal release and dissolution of three locally acting mesalamine formulations in regions of the human gastrointestinal tract","author":"Yu","year":"2016","journal-title":"Pharm. Mol."},{"key":"10.1016\/j.ijpharm.2018.06.050_b0295","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-017-0145-x","article-title":"Mechanistic fluid transport model to estimate gastrointestinal fluid volume and its dynamic change over time","author":"Yu","year":"2017","journal-title":"AAPS J."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318304496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517318304496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T11:36:29Z","timestamp":1569238589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517318304496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0378517318304496"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.050","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded \u201821st Century BA\/BE\u2019 project","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}